Comparative Pharmacology
Head-to-head clinical analysis: ONGLYZA versus SAXAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONGLYZA versus SAXAGLIPTIN.
ONGLYZA vs SAXAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
Saxagliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), which prolongs the action of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
2.5 mg or 5 mg orally once daily
2.5 mg or 5 mg orally once daily irrespective of meals.
None Documented
None Documented
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Clinical Note
moderateSaxagliptin + Gatifloxacin
"Saxagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSaxagliptin + Rosoxacin
"Saxagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSaxagliptin + Levofloxacin
"Saxagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSaxagliptin + Trovafloxacin
"Saxagliptin may increase the hypoglycemic activities of Trovafloxacin."
Terminal half-life: 2.5 hours; accounts for DPP-4 inhibition duration despite rapid clearance.
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Renal (75% as unchanged drug and metabolites; 25% as unchanged drug in urine) and fecal (22% as metabolites).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor